Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Arcylate
2. Argesic
3. Benzoic Acid, 2-hydroxy-, 2-carboxyphenyl Ester
4. Disalcid
5. Disalicylic Acid
6. Mono-gesic
7. Salflex
8. Salicyl Salicylate
9. Salicylsalicylic Acid
10. Saloxium
11. Salsitab
1. 552-94-3
2. Sasapyrine
3. Salicylsalicylic Acid
4. Disalicylic Acid
5. Disalcid
6. 2-carboxyphenyl Salicylate
7. Sasapyrinum
8. Saloxium
9. Salicyloylsalicylic Acid
10. Diacesal
11. Diplosal
12. Sasapirin
13. Sasapyrin
14. Disalyl
15. Nobacid
16. Salical
17. Salina
18. Salysal
19. O-salicylsalicylic Acid
20. Sal Ester Sal
21. 2-(2-hydroxybenzoyl)oxybenzoic Acid
22. Disalicylsaeure
23. Benzoic Acid, 2-hydroxy-, 2-carboxyphenyl Ester
24. Salicylic Acid, Salicylate
25. Nsc-49171
26. Salicylic Acid, Bimolecular Ester
27. Salsalato
28. Salsalatum
29. Salflex
30. Salsalatum [inn-latin]
31. 2-((2-hydroxybenzoyl)oxy)benzoic Acid
32. Salicyloxysalicylic Acid
33. O-salicylcylsalicylsaeure
34. Disalicyclic Acid
35. Sasapyrine (jan)
36. 2-hydroxybenzoic Acid 2-carboxyphenyl Ester
37. Salicylsalicylic Acid;disalicylic Acid
38. Chebi:9014
39. V9mo595c9i
40. Salicylic Acid Bimolecular Ester
41. Nsc49171
42. Ncgc00096014-01
43. Sasapyrine [jan]
44. Dsstox_cid_3572
45. Dsstox_rid_77088
46. Dsstox_gsid_23572
47. Salsalato [inn-spanish]
48. 2-[(2-hydroxybenzoyl)oxy]benzoic Acid (salicylsalicylic Acid)
49. Mono-gesic
50. O-salicyloylsalicylic Acid
51. Disalcid (tn)
52. Cas-552-94-3
53. Salsalate (usp/inn)
54. Einecs 209-027-4
55. Mfcd00020252
56. Nsc 49171
57. 2-salicyloyloxybenzoic Acid
58. Brn 2590908
59. Unii-v9mo595c9i
60. Disalgesic
61. Salicylsalicylic Acid (2-[(2-hydroxybenzoyl)oxy]benzoic Acid)
62. Salsalate [usan:usp:inn:ban]
63. Aspirin Impurity E
64. 2-(2-hydroxybenzoyloxy)benzoic Acid
65. Carboxyphenyl Salicylate
66. Spectrum_001998
67. 2-salicylsalicylic Acid
68. Salsalate [inn]
69. Salsalate [mi]
70. Salsalate [usan]
71. Spectrum2_000693
72. Spectrum3_000173
73. Spectrum4_000940
74. Spectrum5_000670
75. Salsalate [vandf]
76. Salsalate [mart.]
77. Salsalate [usp-rs]
78. Salsalate [who-dd]
79. 2-{[(2-hydroxyphenyl)carbonyl]oxy}benzoic Acid
80. 2-salicyloyloxy-benzoic Acid
81. Schembl15562
82. Bspbio_001665
83. Kbiogr_001500
84. Kbioss_002572
85. Spectrum200331
86. Spbio_000845
87. Acetylsalicylic Acid Impurity E
88. Chembl154111
89. Zinc2062
90. Dtxsid1023572
91. Salsalate [usp Impurity]
92. Salsalate, >=98% (hplc)
93. Bdbm85244
94. Kbio2_002563
95. Kbio2_005131
96. Kbio2_007699
97. Kbio3_001165
98. Salsalate [usp Monograph]
99. Hms2091a05
100. Hms3652p07
101. Hms3885j09
102. Pharmakon1600-00200331
103. Hy-b1245
104. Nsc_5161
105. Benzoic Acid, 2-carboxyphenyl Ester
106. Tox21_111548
107. Ccg-39652
108. Nsc755823
109. S4188
110. Salicylic Acid 2-carboxyphenyl Ester
111. Akos003368478
112. Tox21_111548_1
113. 2-carboxyphenyl Salicylate, Aldrichcpr
114. Cs-4891
115. Db01399
116. Nsc-755823
117. Ncgc00096014-02
118. Ncgc00096014-03
119. Ac-18298
120. As-12645
121. Cas_552-94-3
122. 2-[(2-hydroxybenzoyl)oxy]benzoic Acid #
123. Sbi-0206687.p002
124. Db-020760
125. Ft-0632376
126. Sw219189-1
127. 2-[(2-hydroxyphenyl)carbonyloxy]benzoic Acid
128. C75590
129. D00428
130. Ab01563259_01
131. Ab01563259_02
132. A830578
133. Sr-05000001536
134. Q-100630
135. Q1320691
136. Sr-05000001536-1
137. Acetylsalicylic Acid Impurity E [ep Impurity]
138. Salsalate, United States Pharmacopeia (usp) Reference Standard
139. Aspirin Impurity E; 2-hydroxybenzoic Acid 2-carboxyphenyl Ester; Salicylic Acid Salicylate; 2-hydroxybenzoic Acid 2-carboxyphenyl Ester
140. Salsalate (aspirin Impurity E), Pharmaceutical Secondary Standard; Certified Reference Material
Molecular Weight | 258.23 g/mol |
---|---|
Molecular Formula | C14H10O5 |
XLogP3 | 3 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 4 |
Exact Mass | 258.05282342 g/mol |
Monoisotopic Mass | 258.05282342 g/mol |
Topological Polar Surface Area | 83.8 Ų |
Heavy Atom Count | 19 |
Formal Charge | 0 |
Complexity | 341 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
For relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorders.
Salsalate is a nonsteroidal anti-inflammatory agent for oral administration. Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established. In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo.
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
N - Nervous system
N02 - Analgesics
N02B - Other analgesics and antipyretics
N02BA - Salicylic acid and derivatives
N02BA06 - Salsalate
Absorption
Salsalate is insoluble in acid gastric fluids (< 0.1 mg/ml at pH 1.0), but readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged. The amount of salicylic acid available from salsalate is about 15% less than from aspirin, when the two drugs are administered on a salicylic acid molar equivalent basis (3.6 g salsalate/5 g aspirin). Food slows the absorption of all salicylates including salsalate.
Salsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body.
The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.
The mode of anti-inflammatory action of salsalate and other nonsteroidal anti-inflammatory drugs is not fully defined, but appears to be primarily associated with inhibition of prostaglandin synthesis. This inhibition of prostaglandin synthesis is done through the inactivation of cyclooxygenase-1 (COX-1) and COX-2, which are reponsible for catalyzing the formation of prostaglandins in the arachidonic acid pathway. Although salicylic acid (the primary metabolite of salsalate) is a weak inhibitor of prostaglandin synthesis in vitro, salsalate appears to selectively inhibit prostaglandin synthesis in vivo, providing anti-inflammatory activity equivalent to aspirin and indomethacin. Unlike aspirin, salsalate does not inhibit platelet aggregation.
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
23
PharmaCompass offers a list of Salsalate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Salsalate manufacturer or Salsalate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Salsalate manufacturer or Salsalate supplier.
PharmaCompass also assists you with knowing the Salsalate API Price utilized in the formulation of products. Salsalate API Price is not always fixed or binding as the Salsalate Price is obtained through a variety of data sources. The Salsalate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Argesic manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Argesic, including repackagers and relabelers. The FDA regulates Argesic manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Argesic API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Argesic manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Argesic supplier is an individual or a company that provides Argesic active pharmaceutical ingredient (API) or Argesic finished formulations upon request. The Argesic suppliers may include Argesic API manufacturers, exporters, distributors and traders.
click here to find a list of Argesic suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Argesic DMF (Drug Master File) is a document detailing the whole manufacturing process of Argesic active pharmaceutical ingredient (API) in detail. Different forms of Argesic DMFs exist exist since differing nations have different regulations, such as Argesic USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Argesic DMF submitted to regulatory agencies in the US is known as a USDMF. Argesic USDMF includes data on Argesic's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Argesic USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Argesic suppliers with USDMF on PharmaCompass.
A Argesic written confirmation (Argesic WC) is an official document issued by a regulatory agency to a Argesic manufacturer, verifying that the manufacturing facility of a Argesic active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Argesic APIs or Argesic finished pharmaceutical products to another nation, regulatory agencies frequently require a Argesic WC (written confirmation) as part of the regulatory process.
click here to find a list of Argesic suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Argesic as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Argesic API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Argesic as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Argesic and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Argesic NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Argesic suppliers with NDC on PharmaCompass.
Argesic Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Argesic GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Argesic GMP manufacturer or Argesic GMP API supplier for your needs.
A Argesic CoA (Certificate of Analysis) is a formal document that attests to Argesic's compliance with Argesic specifications and serves as a tool for batch-level quality control.
Argesic CoA mostly includes findings from lab analyses of a specific batch. For each Argesic CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Argesic may be tested according to a variety of international standards, such as European Pharmacopoeia (Argesic EP), Argesic JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Argesic USP).